
    
      The primary objective of this study is to increase the overall survival of the study subjects
      by providing expanded access to Lucanix. Overall survival and progression-free survivals will
      be compared with historical controls.

      The secondary objectives of this study are:

        -  Evaluate the best overall tumor response.

        -  Evaluate progression-free survival (PFS).

        -  Evaluate treatment toxicity.
    
  